The global equitant-palonosetron FDC market accounted for USD 324.32 billion in 2023 and is expected to reach USD 1.00 trillion by 2034 with a CAGR of 10.82% during the forecast period 2024-2034. Efficiency in the management of chemotherapy-induced nausea and vomiting (CINV), rising cancer incidence and treatment rates, a preference for combination therapies, advances in pharmaceutical formulations, and regulatory approvals and reimbursement policies will all fuel market expansion.
Netupitant-Palonosetron FDC is more effective at preventing CINV than standard antiemetic drugs. Its dual mechanism of action addresses both the acute and delayed phases of CINV, offering total relief to patients receiving chemotherapy. The rising global prevalence of cancer fuels the market for supportive care pharmaceuticals such as Netupitant-Palonosetron FDC. Rising awareness, early detection, and breakthroughs in cancer treatment all lead to increased chemotherapy consumption, which expands the market for CINV preventive medicines. For instance, in April 2022, Helsinn Group announced the start of a Phase 3 trial for their NETINOX (netupitant/palonosetron FDC) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients.
By type, the capsules segment accounted for the highest revenue-grossing segment in the global equitant-palonosetron FDC market in 2023 owing to the increased preference for oral dosage forms and ease of administration for patients undergoing chemotherapy. For instance, Sandoz stated in January 2023 that its generic version of the Netupitant-Palonosetron FDC would be available in the United States, providing an economical alternative for chemotherapy patients. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to the expansion of distribution channels, including online pharmacies, and increasing adoption of Netupitant-Palonosetron FDC in emerging markets.
By distribution channel, the retail pharmacy segment accounted for the highest revenue-grossing segment in the global equitant-palonosetron FDC market in 2023 owing to the increasing accessibility and availability of the medication for outpatient prescriptions, coupled with rising awareness among patients and healthcare providers. For instance, in September 2022, Dr. Reddy's Laboratories announced the availability of a generic version of Netupitant-Palonosetron FDC in the United States, expanding its portfolio of oncology supportive care drugs. Additionally, the online pharmacy segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising consumer preference for convenience, expanding e-commerce platforms, and increasing adoption of online healthcare services.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high cancer incidence rates, advanced healthcare infrastructure, and strong reimbursement policies supporting the use of Netupitant-Palonosetron FDC. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing cancer prevalence, improving healthcare access, and rising adoption of advanced cancer treatment modalities, including Netupitant-Palonosetron FDC. For instance, Glenmark Pharmaceuticals announced the launch of its generic version of Netupitant-Palonosetron FDC in the United States in October 2023, thereby boosting its oncology range.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Netupitant-Palonosetron FDC is more effective at preventing CINV than standard antiemetic drugs. Its dual mechanism of action addresses both the acute and delayed phases of CINV, offering total relief to patients receiving chemotherapy. The rising global prevalence of cancer fuels the market for supportive care pharmaceuticals such as Netupitant-Palonosetron FDC. Rising awareness, early detection, and breakthroughs in cancer treatment all lead to increased chemotherapy consumption, which expands the market for CINV preventive medicines. For instance, in April 2022, Helsinn Group announced the start of a Phase 3 trial for their NETINOX (netupitant/palonosetron FDC) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients.
By type, the capsules segment accounted for the highest revenue-grossing segment in the global equitant-palonosetron FDC market in 2023 owing to the increased preference for oral dosage forms and ease of administration for patients undergoing chemotherapy. For instance, Sandoz stated in January 2023 that its generic version of the Netupitant-Palonosetron FDC would be available in the United States, providing an economical alternative for chemotherapy patients. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to the expansion of distribution channels, including online pharmacies, and increasing adoption of Netupitant-Palonosetron FDC in emerging markets.
By distribution channel, the retail pharmacy segment accounted for the highest revenue-grossing segment in the global equitant-palonosetron FDC market in 2023 owing to the increasing accessibility and availability of the medication for outpatient prescriptions, coupled with rising awareness among patients and healthcare providers. For instance, in September 2022, Dr. Reddy's Laboratories announced the availability of a generic version of Netupitant-Palonosetron FDC in the United States, expanding its portfolio of oncology supportive care drugs. Additionally, the online pharmacy segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising consumer preference for convenience, expanding e-commerce platforms, and increasing adoption of online healthcare services.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high cancer incidence rates, advanced healthcare infrastructure, and strong reimbursement policies supporting the use of Netupitant-Palonosetron FDC. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing cancer prevalence, improving healthcare access, and rising adoption of advanced cancer treatment modalities, including Netupitant-Palonosetron FDC. For instance, Glenmark Pharmaceuticals announced the launch of its generic version of Netupitant-Palonosetron FDC in the United States in October 2023, thereby boosting its oncology range.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Netupitant-Palonosetron FDC Market Report 2023 - 2034
Netupitant-Palonosetron FDC Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Flakes
- Capsules
- Other
Netupitant-Palonosetron FDC Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacy
- Online Pharmacy
Netupitant-Palonosetron FDC Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Netupitant-Palonosetron FDC Market: Type Estimates & Trend Analysis
8. Netupitant-Palonosetron FDC Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Netupitant-Palonosetron FDC Market
11. Europe Global Netupitant-Palonosetron FDC Market
12. Asia Pacific Global Netupitant-Palonosetron FDC Market
13. Latin America Global Netupitant-Palonosetron FDC Market
14. MEA Global Netupitant-Palonosetron FDC Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Glenmark Pharmaceuticals Ltd.
- Cipla Inc.
- Lupin Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Ltd.
- Fresenius Kabi AG
- Apotex Inc.
- Pfizer Inc.
- Aurobindo Pharma Limited
- Taro Pharmaceutical Industries Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 324.32 Billion |
| Forecasted Market Value ( USD | $ 1004.09 Billion |
| Compound Annual Growth Rate | 10.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
